Protagonist Therapeutics PTGX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's EBITDA margin?
- Protagonist Therapeutics (PTGX) reported EBITDA margin of -190.4% in Q1 2026.
- How has Protagonist Therapeutics's EBITDA margin changed year-over-year?
- Protagonist Therapeutics's EBITDA margin decreased by 1510.4% year-over-year, from 13.5% to -190.4%.
- What is the long-term trend for Protagonist Therapeutics's EBITDA margin?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's EBITDA margin has grown at a -9.3% compound annual growth rate (CAGR), from -457% to -340.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.